Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 5—May 2011


Severe Imported Plasmodium falciparum Malaria, France, 1996–2003

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at; (4) view/print certificate.

Release date: April 22, 2011; Expiration date: April 22, 2012

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe the diagnosis and prognosis of malaria among travelers
  • Distinguish characteristics of returning travelers with malaria in the current study
  • Analyze variables associated with a higher risk for severe malaria among returning travelers

Medscape CME Editor

Beverly Merritt, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Beverly Merritt has disclosed no relevant financial relationships.

Medscape CME Author

Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.


Disclosures: Elise Seringe, MD; Marc Thellier, MD; Arnaud Fontanet, MD; Fabrice Legros, MD; Olivier Bouchaud, PhD; Thierry Ancelle, MD; Eric Kendjo; Sandrine Houze, MD; Martin Danis, MD; and Rémy Durand, MD, have disclosed no relevant financial relationships. Jacques Le Bras, PhD, has disclosed the following relevant financial relationships: received grants for clinical research from GlaxoSmithKline; received grant from GlaxoSmithKline on application of AFSSAPS phase 4 requirement on Malarone.


Article Navigation